Refers to a compound of formula (1), where a is (a), (b), among others x1, X2, X3 and X4 are independently or CR11, X5, X6, X7 and x8 are independently or cr12 N Z is replaced or not replaced with 1 - 2 groups R7 R1, R2 and R3 are H or alkyl of C1 - 6 R5 is Halo, cyano, among others R7 is H Halo, cyano, among others, R11 and R12 are independently h, Halo, cyano, alkoxyl C1 - 6Among others n is 0 - 3. Is the preferred compound: phenyl - N - (4 - [4 - (4 - il pyridazin-3) phenyl] methyl] benzamide among others. Also referred to a Pharmaceutical Composition and a process of production. This Compound is an inhibitor of the Wnt Signalling Pathway is useful for the treatment of fibrosis, Osteoarthritis, macular degenerationSE REFIERE A UN COMPUESTO DE FORMULA (1), DONDE: A ES a), b), ENTRE OTROS X1, X2, X3, Y X4 SON INDEPENDIENTEMENTE N O CR11 X5, X6, X7 Y X8 SON INDEPENDIENTEMENTE N O CR12 Z ES NO SUSTITUIDO O SUSTITUIDO POR 1-2 GRUPOS R7 R1, R2 Y R3 SON H O ALQUILO C1-6 R5 ES HALO, CIANO, ENTRE OTROS R7 ES H, HALO, CIANO, ENTRE OTROS R11 Y R12 SON INDEPENDIENTEMENTE H, HALO, CIANO, ALCOXILO C1-6, ENTRE OTROS n ES DE 0-3. ES COMPUESTO PREFERIDO: 4-FENIL-N-{[4-(PIRIDAZIN-4-IL)FENIL]METIL}BENZAMIDA ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PRODUCCION. DICHO COMPUESTO ES INHIBIDOR DE LA VIA DE SENALIZACION DE WNT SIENDO UTIL PARA EL TRATAMIENTO DE FIBROSIS, OSTEOARTRITIS, DEGENERACION MACULAR
